VISTAGEN THERAPEUTICS INC (VTGN)

Company Profile

VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.

Company Info

VISTAGEN THERAPEUTICS INC

343 Allerton Avenue

South San Francisco CALIFORNIA 94080

P: 16505773600

CEO: Shawn K. Singh

Employees: 45

Website: https://www.vistagen.com/